Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11

By Ben Zigterman · April 23, 2024, 5:53 PM EDT

Insolvent biotechnology company Eiger BioPharmaceuticals Inc. received approval Tuesday at a hearing in Texas to sell its drug treatment for a rare genetic disorder to Sentynl Therapeutics, a subsidiary of Indian drugmaker Zydus...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Eiger BioPharmaceuticals Inc. filed for Chapter 11 protection in Texas bankruptcy court with $53.1 million of debt and plans to sell its assets during the case.

Case Number

8:24-bk-80040

Judge

Stacey Jernigan

Venue

U.S. Bankruptcy Court for the Northern District of Texas

Capital Structure

Total Liabilities:

$53.1 million

View Full Scorecard

Related Sections

Case Information

Case Title

Eiger BioPharmaceuticals, Inc.

Case Number

8:24-bk-80040

Court

Texas Northern

Nature of Suit

Date Filed

April 01, 2024

Recent Articles By Ben